InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the discovery and development of inhibitors using C5a technology. The company's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody undergoing clinical trials for the treatment of various inflammatory diseases, including hidradenitis suppurativa, anti-neutrophil cytoplasm antibody associated vasculitis, pyoderma gangraenosum, and PD-1/PD-L1 inhibitor resistant/refractory cutaneous squamous cell carcinoma. In addition, InflaRx N.V. is developing INF904, an oral small molecule drug candidate, and IFX002 for chronic inflammation and autoimmune diseases. The company has co-development and clinical trial collaboration agreements with other biotechnology and pharmaceutical companies.

Products

• Vilobelimab (anti-C5a monoclonal antibody)

• INF904 (oral small molecule drug candidate)

• IFX002 (pre-clinical development stage drug)